Research Article
RAGE - A Versatile Drug Target for Alzheimer’s Disease
@INPROCEEDINGS{10.4108/eai.7-12-2021.2315103, author={Palaniswamy Rani and Balasubramanian Ayshwariya and Saravanakumar Vinodh}, title={RAGE - A Versatile Drug Target for Alzheimer’s Disease}, proceedings={Proceedings of the First International Conference on Combinatorial and Optimization, ICCAP 2021, December 7-8 2021, Chennai, India}, publisher={EAI}, proceedings_a={ICCAP}, year={2021}, month={12}, keywords={alzheimer’s disease cognitive impairment rage amyloid beta neurodegeneration drug development}, doi={10.4108/eai.7-12-2021.2315103} }- Palaniswamy Rani
Balasubramanian Ayshwariya
Saravanakumar Vinodh
Year: 2021
RAGE - A Versatile Drug Target for Alzheimer’s Disease
ICCAP
EAI
DOI: 10.4108/eai.7-12-2021.2315103
Abstract
Alzheimer's disease (AD) is a chronic neurodegenerative disease which accounts for 60–70% cases of dementia. Worldwide, around 50 million people are affected by dementia and every year nearly 10 million new cases are being reported. Major cause of AD is abnormal accumulation of amyloid beta in the brain cells which in turn forms neurofibrillary tangles that leads to failure of synaptic transmission and neuronal degeneration. Deposition of amyloid beta is governed by various factors in which Receptor for advanced glycation end products (RAGE) plays a critical role in pathogenesis of AD. RAGE is a key pattern recognition receptor of the innate immune response and mediates diverse physiological and pathological effects through cellular signaling pathways leading to inflammatory reactions. In this context, the potential role of RAGE in cognitive impairment and as therapeutic target for AD is an interesting topic to review. In this essence, this review emphasis on RAGE and its isoforms in human, pattern recognition of RAGE for diverse ligands, role of RAGE in AD through RAGE and amyloid beta interaction, involvement of RAGE activated signaling pathways in neuro-inflammation, role of sRAGE in amyloid beta clearance, sRAGE as therapeutics for AD and development of RAGE inhibitors. This chapter overviews RAGE as potential therapeutic targets for Alzheimer’s disease.
